Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection

Tacrolimus has been widely applied to prevent organ rejection after transplantation. However, the conventional pharmaceutical formulation of tacrolimus limits its applications in ocular therapy due to its hydrophobicity and low corneal penetrability. We optimized tacrolimus-loaded methoxy poly (ethy...

Full description

Bibliographic Details
Main Authors: Qianni Wu, Dong Liu, Xulin Zhang, Dongni Wang, Meimei DongYe, Wan Chen, Duoru Lin, Fangming Zhu, Weirong Chen, Haotian Lin
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Drug Delivery
Subjects:
Online Access:http://dx.doi.org/10.1080/10717544.2019.1582728
id doaj-31345c9c0d7c4ef495360634236d94a0
record_format Article
spelling doaj-31345c9c0d7c4ef495360634236d94a02020-11-25T02:09:57ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642019-01-0126129029910.1080/10717544.2019.15827281582728Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejectionQianni Wu0Dong Liu1Xulin Zhang2Dongni Wang3Meimei DongYe4Wan Chen5Duoru Lin6Fangming Zhu7Weirong Chen8Haotian Lin9Zhongshan Ophthalmic Center, Sun Yat-sen UniversitySun Yat–sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversitySun Yat–sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen UniversityTacrolimus has been widely applied to prevent organ rejection after transplantation. However, the conventional pharmaceutical formulation of tacrolimus limits its applications in ocular therapy due to its hydrophobicity and low corneal penetrability. We optimized tacrolimus-loaded methoxy poly (ethylene glycol-block-poly (d, l)-lactic-co-glycolic acid) nanoparticles (TAC-NPs) by simple and effective nanotechnology as a drug delivery system for corneal graft rejection to overcome these drawbacks. The prepared TAC-NPs were 82.9 ± 1.3 nm in size, and the drug loading and encapsulation efficiency were 8.01 ± 0.23% and 80.10 ± 2.33%. Furthermore, New Zealand rabbits were used to analyze the single-dose pharmacokinetics of the TAC-NPs using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). In rats with allogenic penetrating keratoplasty, the administration of TAC-NPs dispersion drops improved the TAC concentrations in the aqueous humor and cornea, consistent with a significantly higher effective inhibition of IL-2, IL-17, and VEGF expression compared with conventional 0.1% tacrolimus drops. Meanwhile, we also compared two different topical administration methods (including eye drop and subconjunctival injection) of TAC-NPs to maximize the sustained release characteristic of NPs. In summary, the small-sized TAC-NPs enhanced transcorneal permeation and absorption of TAC and more effectively inhibited corneal allograft rejection, which indicated that biodegradable polymeric nanomaterials-based drug delivery system had great potential for improving the clinical therapy efficacy of hydrophobic drugs.http://dx.doi.org/10.1080/10717544.2019.1582728tacrolimusmpeg-b-plgananoparticleskeratoplastyimmune rejection
collection DOAJ
language English
format Article
sources DOAJ
author Qianni Wu
Dong Liu
Xulin Zhang
Dongni Wang
Meimei DongYe
Wan Chen
Duoru Lin
Fangming Zhu
Weirong Chen
Haotian Lin
spellingShingle Qianni Wu
Dong Liu
Xulin Zhang
Dongni Wang
Meimei DongYe
Wan Chen
Duoru Lin
Fangming Zhu
Weirong Chen
Haotian Lin
Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
Drug Delivery
tacrolimus
mpeg-b-plga
nanoparticles
keratoplasty
immune rejection
author_facet Qianni Wu
Dong Liu
Xulin Zhang
Dongni Wang
Meimei DongYe
Wan Chen
Duoru Lin
Fangming Zhu
Weirong Chen
Haotian Lin
author_sort Qianni Wu
title Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
title_short Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
title_full Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
title_fullStr Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
title_full_unstemmed Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
title_sort development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
publisher Taylor & Francis Group
series Drug Delivery
issn 1071-7544
1521-0464
publishDate 2019-01-01
description Tacrolimus has been widely applied to prevent organ rejection after transplantation. However, the conventional pharmaceutical formulation of tacrolimus limits its applications in ocular therapy due to its hydrophobicity and low corneal penetrability. We optimized tacrolimus-loaded methoxy poly (ethylene glycol-block-poly (d, l)-lactic-co-glycolic acid) nanoparticles (TAC-NPs) by simple and effective nanotechnology as a drug delivery system for corneal graft rejection to overcome these drawbacks. The prepared TAC-NPs were 82.9 ± 1.3 nm in size, and the drug loading and encapsulation efficiency were 8.01 ± 0.23% and 80.10 ± 2.33%. Furthermore, New Zealand rabbits were used to analyze the single-dose pharmacokinetics of the TAC-NPs using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). In rats with allogenic penetrating keratoplasty, the administration of TAC-NPs dispersion drops improved the TAC concentrations in the aqueous humor and cornea, consistent with a significantly higher effective inhibition of IL-2, IL-17, and VEGF expression compared with conventional 0.1% tacrolimus drops. Meanwhile, we also compared two different topical administration methods (including eye drop and subconjunctival injection) of TAC-NPs to maximize the sustained release characteristic of NPs. In summary, the small-sized TAC-NPs enhanced transcorneal permeation and absorption of TAC and more effectively inhibited corneal allograft rejection, which indicated that biodegradable polymeric nanomaterials-based drug delivery system had great potential for improving the clinical therapy efficacy of hydrophobic drugs.
topic tacrolimus
mpeg-b-plga
nanoparticles
keratoplasty
immune rejection
url http://dx.doi.org/10.1080/10717544.2019.1582728
work_keys_str_mv AT qianniwu developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT dongliu developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT xulinzhang developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT dongniwang developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT meimeidongye developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT wanchen developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT duorulin developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT fangmingzhu developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT weirongchen developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
AT haotianlin developmentandeffectsoftacrolimusloadednanoparticlesontheinhibitionofcornealallograftrejection
_version_ 1724921498849771520